eWe assessed the performance of the Ceeram and Altona assays, the first two commercially available hepatitis E virus (HEV) RNA assays, using serial dilutions of 4 HEV-positive reference samples (genotypes 3a, 3c, 3e, and 3f). Both assays provided good analytical sensitivity and high reproducibility for detecting genotype 3 HEV RNA.H epatitis E virus (HEV) is becoming increasingly important in industrialized countries (1, 2). Four main genotypes and several subtypes have been identified (3). Most infections in industrialized countries are due to zoonotic transmission, often of genotype 3 (HEV3); subtypes 3a and 3b are frequent in North America and Japan, and subtypes 3c, 3e, and 3f are more prevalent in Europe (3-5). HEV3 is an emerging concern for immunocompromised patients, as it can lead to chronic infection and cirrhosis (6-12).As evaluations of anti-HEV IgM assays revealed appreciable variations in their performances (13,14), it is important to diagnose HEV infections by detecting HEV RNA. Several in-house reverse transcription-PCRs (RT-PCRs) were recently evaluated, and their sensitivities were shown to differ greatly (15). We have also shown that genotype 3 diversity can influence the quantification of HEV RNA (16).We have therefore assessed the performance of two newly available commercial HEV RNA assays, the Ceeram and Altona assays. We tested their ability to detect HEV RNA, particularly those subtypes of HEV3 that are most prevalent in industrialized countries.We used the HEV RNA WHO international standard (WHO/ BS/2011.2175), which is a HEV genotype 3a strain quantified at 250,000 IU/ml. Samples of HEV genotypes 3c, 3e, and 3f were collected from patients in France (17, 18). Each sample was diluted in HEV-negative plasma and quantified with a validated in-house RT-PCR protocol using a transcribed RNA as the quantification standard (1 IU/ml corresponds to 1.25 copies/ml) (16). HEV RNA was extracted from blood samples (140 l) with the RNeasy minikit according to the manufacturer's instructions (Qiagen, Courtaboeuf, France). The HepatitisE@ceeramTools kit by Ceeram (La Chapelle sur Erdre, France) and the RealStar HEV RT-PCR kit, version 1.0, by Altona Diagnostics (Eurobio, Courtaboeuf, France) were used with the Light Cycler 480 instrument (Roche Diagnostics, Meylan, France) according to the manufacturers' instructions. The threshold cycle (C T ) value of each sample was determined.The linearity of both assays was assessed with serial dilutions of the WHO HEV reference standard. The Ceeram assay was linear from 100 to 250,000 IU/ml, and the Altona assay was linear from 20 to 250,000 IU/ml (Fig. 1). The standard curves gave amplification efficiencies of 2.08 for the Ceeram assay and 2.3 for the Altona assay. Reproducibility was estimated from the C T values for each dilution. The mean standard deviations were 0.7 C T (range: 0.4 to 1.6 C T ) for the Ceeram RT-PCR and 0.4 C T (range: 0.1 to 1.4 C T ) for the Altona RT-PCR.We assayed samples of strains 3a, 3c, 3e, and 3f to assess analytical sensitivity. Th...